Diprivan — Competitive Intelligence Brief

Diprivan (Propofol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic. Area: Neuroscience.

marketed General anesthetic GABA A receptors Neuroscience Small molecule

Target snapshot

Diprivan (Propofol) — Fresenius Kabi. Propofol produces sedative/anesthetic effects by positive modulation of inhibitory GABA function through GABA A receptors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diprivan TARGET	Propofol	Fresenius Kabi	marketed	General anesthetic	GABA A receptors	1989-01-01
Ambien	zolpidem	Sanofi	marketed		α1 subunit containing GABA A receptors
SEVOFLURANE	SEVOFLURANE		marketed	General Anesthetic [EPC]		1995-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01
PROPOFOL	PROPOFOL		marketed	General Anesthetic [EPC]		1989-01-01
Amidate	ETOMIDATE	Pfizer	marketed	General Anesthetic [EPC]	Cytochrome P450 11B2, mitochondrial	1982-01-01
Forane	ISOFLURANE	Baxter	marketed	General Anesthetic [EPC]	5-hydroxytryptamine receptor 2B	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Chung-Ang University Gwangmyeong Hospital · 1 drug in this class
3. Fresenius Kabi · 1 drug in this class
4. Gangnam Severance Hospital · 1 drug in this class
5. Rigshospitalet, Denmark · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Universidade Estadual Paulista Júlio de Mesquita Filho · 1 drug in this class
8. University Health Network, Toronto · 1 drug in this class
9. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class